Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe ...

Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) ...

Lantheus Holdings, Inc.'s stock soars 55%, fueled by Pylarify and strategic acquisitions in Alzheimer's and oncology. Click ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Patent provides coverage into 2040 for key aspects of the bioreactor ... we caution you that these statements are based on a combination of facts and factors currently known by us and our projections ...

December 31, 2024 -- NAARDEN, the Netherlands and MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical ...

today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,195,439 (the ‘439 patent) on January 14, 2025. Entitled "Cl-Substituted Isopropylamine Fused ...

MAGA references on a library plaque have divided the Southern California surf town and thrust it into the national spotlight. By Orlando Mayorquín They call themselves the “MAGA-nificent 7.” ...

Furthermore, CTT is actively working on strengthening our patents in the United States and Europe and will look to file provisional patents in 2025 to continue to protect and strengthen our technology ...

A US Patent and Trademark Office executive who managed key appeals at the agency’s tribunal and previously served as solicitor accepted President Donald Trump‘s voluntary resignation officer for ...

Teva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab). The product is indicated for the ...